Cellectis Approves 29 Resolutions, Rejects 30th with 55.84% Voting Turnout
CLLS•Cellectis held its June 25 shareholders meeting in Paris, where 55.84% of voting rights were exercised. Shareholders adopted resolutions 1–29 and rejected resolution 30 as recommended by the board of directors.
1. Meeting Logistics and Participation
Cellectis convened its annual general shareholders meeting on June 25, 2026, at the Biopark auditorium in Paris. The meeting commenced at 2:30 p.m. CET, with 55.84% of voting rights represented either in person or by proxy.
2. Voting Results and Resolutions Adopted
Shareholders voted on 30 resolutions covering board appointments, statutory approvals and governance updates. Resolutions 1 through 29, including the reappointment of directors and authorization of share issuances, were approved by a majority of votes cast.
3. Resolution 30 Rejected
The only resolution voted down was resolution 30, which failed to secure the required majority despite the board’s recommendation. This outcome reflects shareholder scrutiny on the specific proposal contained in that motion.
4. Governance Impact and Outlook
The approved resolutions will streamline corporate governance and fund future R&D activities in Cellectis’ gene-editing platform. Detailed vote tallies and full text of each resolution are published on the company website for investor review.
